Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;14(12):2958.
doi: 10.3390/cancers14122958.

Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer

Affiliations

Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer

Leandra Piscopo et al. Cancers (Basel). .

Abstract

Background: Hybrid positron emission tomography (PET)/magnetic resonance (MR) is an emerging imaging modality with great potential to provide complementary data acquired at the same time, under the same physiological conditions. The aim of this study was to evaluate the prognostic value of hybrid 18F-fluorodeoxyglucose (FDG) PET/MR in patients with differentiated thyroid cancer (DTC) who underwent total thyroidectomy and radioactive iodine therapy for suspicion of disease relapse. Methods: Between November 2015 and February 2017, 55 patients underwent hybrid 18F-FDG PET/MR. Assessment of positive MR was made considering all sequences in terms of malignancy based on the morphological T2-weighted features and the presence of restricted diffusivity on diffusion-weighted imaging images and both needed to be positive on the same lesion. Both foci with abnormal 18F-FDG uptake, which corresponded to tissue abnormalities on the MR, and tracer accumulation, which did not correspond to normal morphological structures, were considered positive. Results: During follow-up (mean 42 ± 27 months), 29 patients (53%) had disease recurrence. In the Cox univariate regression analysis age, serum Tg level ≥ 2 ng/mL, positive short tau inversion recovery (STIR), and positive PET were significant predictors of DTC recurrence. Kaplan−Meier survival analyses showed that patients with Tg ≥ 2 ng/mL had poorer outcomes compared to those with serum Tg level < 2 ng/mL (p < 0.05). Similarly, patients with positive STIR and positive PET had a worst outcome compared to those with negative STIR (p < 0.05) and negative PET (p < 0.005). Survival analysis performed in the subgroup of 36 subjects with Tg level ≥ 2 ng/mL revealed that patients with positive PET had a worst outcome compared to those with negative PET (p < 0.05). Conclusions: Age, serum Tg level ≥ 2 ng/mL, positive STIR, and positive 18F-FDG PET were significant predictors of DTC recurrence. However, the serum Tg level was the only independent predictor of DTC. Hybrid PET/MR imaging may have the potential to improve the information content of one modality with the other and would offer new opportunities in patients with DTC. Thus, further studies in a larger patient population are needed to understand the additional value of 18F-FDG PET/MR in patients with DTC.

Keywords: PET/MR; differentiated thyroid carcinoma; hybrid imaging; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Venn diagram: 14 patients were PET+ and 13 patients MR+; the overlap of these groups is represented by 8 patients.
Figure 2
Figure 2
Kaplan–Meier survival analysis according to serum Tg levels. The navy line indicates patients with Tg < 2 ng/mL and the red line patients with Tg ≥ 2 ng/mL.
Figure 3
Figure 3
Kaplan–Meier survival analysis according to the PET findings in the subgroup of 36 patients with Tg level ≥ 2 ng/mL. The navy line indicates patients with negative PET and the red line patients with positive PET.
Figure 4
Figure 4
Example of a lesion detected in the right digastric jugular space at MR with inhomogeneous hyperintensity in the T2 sequences (A), restricted diffusivity in the DWI sequences (B), and increased uptake of 18F-FDG on PET (C) and PET/MR (D).

References

    1. Kim S.-J., Myong J.P., Suh H., Lee K.E., Youn Y.-K. Optimal cutoff age for predicting mortality associated with differentiated thyroid cancer. PLoS ONE. 2015;10:e0130848. doi: 10.1371/journal.pone.0130848. - DOI - PMC - PubMed
    1. Vrachimis A., Wenning C., Gerss J., Dralle H., Tabassi M.V., Schober O., Schober O., Riemann B., on behalf of The MSDS Study Group Not all DTC patients with N positive disease deserve the attribution “high risk”. contribution of the MSDS trial. J. Surg. Oncol. 2015;112:9–14. doi: 10.1002/jso.23948. - DOI - PubMed
    1. Shaha A.R. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114:393–402. doi: 10.1097/00005537-200403000-00001. - DOI - PubMed
    1. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. - DOI - PMC - PubMed
    1. Klain M., Nappi C., Zampella E., Cantoni V., Green R., Piscopo L., Volpe F., Manganelli M., Caiazzo E., Petretta M., et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: A systematic review and a meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:4437–4444. doi: 10.1007/s00259-021-05440-x. - DOI - PMC - PubMed

LinkOut - more resources